Association for Molecular Pathology Annual Meeting & Expo 2024

Association for Molecular Pathology Annual Meeting & Expo 2024

 Include: 107 videos + 2 pdfs, size: 50.8 GB

The Association for Molecular Pathology (AMP) Annual Meeting & Expo 2024 is the premier global gathering for professionals advancing the science and practice of molecular pathology. This year’s program delivers cutting-edge research, innovative technologies, and real-world clinical applications that are shaping the future of precision medicine. Featuring expert-led sessions, interactive workshops, and an extensive industry expo, the meeting provides a unique opportunity to stay ahead in the rapidly evolving landscape of molecular diagnostics.

What You Will Learn

• Breakthroughs in molecular diagnostics, genomics, and biomarker discovery

• Clinical applications in oncology, infectious diseases, and inherited disorders

• Advances in next-generation sequencing, liquid biopsy, and digital pathology

• Best practices for integrating new molecular technologies into clinical care

• Updates on regulatory frameworks, reimbursement policies, and quality assurance

Event Details

• Event: Association for Molecular Pathology Annual Meeting & Expo 2024

• Format: In-person conference with hybrid participation options

• Program Highlights: Keynote presentations, scientific sessions, poster discussions, and industry exhibitions

• Topics Covered: Emerging technologies, personalized medicine, diagnostic innovations, and bioinformatics solutions

Who Should Attend
Molecular pathologists, clinical laboratory directors, medical geneticists, oncologists, infectious disease specialists, researchers, and laboratory professionals. It is also ideal for biotechnology and pharmaceutical professionals, regulatory specialists, and trainees in molecular medicine.

Why Attend
This meeting is a must-attend for anyone seeking to deepen their expertise, explore the latest innovations, and connect with leaders in molecular pathology. Attendees will gain actionable insights, strengthen their professional network, and leave equipped to implement cutting-edge diagnostics and therapeutic strategies in clinical and research settings.

+ Topics:

Programs & Schedules

• AMP 2024 Workshop Program

• AMP On-Site Program Overview

Precision Oncology & CGP

• Comprehensive Genomic Profiling (CGP) in Solid & Hematologic Malignancies

• Actionable Biomarkers in Early-Stage NSCLC

• BRAF Mutations in Metastatic Colorectal Cancer

• Gene Fusion Detection Strategies for Oncology

• Whole Exome Sequencing in Solid Tumors—Clinical Impact

• Radiogenomics: Integrating Molecular and Imaging Data

• Tumor Mutational Burden: Validation & Reporting (AMP/CAP/SITC)

Liquid Biopsy, ctDNA & MRD

• Pan-Cancer Liquid Biopsy: Technologies & Early Detection

• ctDNA Genotyping in NSCLC—Fast, Comprehensive Workflows

• MRD Testing in AML: Strategies & Pitfalls

• Ultra-Sensitive MRD with Whole-Genome ppmSeq

• Cell-Free DNA for MRD in Lymphoid Malignancies

NGS, PCR & Advanced Assays

• NGS Implementation Journeys: Hospital & Academic Labs

• Rapid NGS for Myeloid/Lymphoid Malignancies

• Amplicon-Based NGS: End-to-End CGP Solutions

• 32-Target Multiplex RT-PCR in 10 Minutes (POC)

• Droplet Digital PCR (ddPCR) in Precision Oncology & MRD

• Long-Range PCR + Long-Read Sequencing for Hard Genes

• qPCR Exosome Workflows for ESR1 & Beyond

Structural Genomics & Spatial Omics

• Optical Genome Mapping (OGM) in Leukemia, Lymphoma & Sarcoma

• OGM + Long-Read Sequencing for Structural Variants

• High-Throughput Spatial Multiomics for Biomarker Discovery

• Highly Multiplexed Spatial Transcriptomics in NSCLC

Pharmacogenomics (PGx)

• Guideline-Driven PGx Testing (AMP Tier 1–2)

• Enterprise-Wide PGx: Practical Integration

• Pharmacists’ Roles in Clinical PGx

• Global PGx Recommendations (AMP/ACMG/CPIC/CAP/DPWG/ESPT/PharmGKB/PharmVar)

Breast Cancer Focus

• ESR1 Mutations & ctDNA in Metastatic HR+/HER2- Breast Cancer

• PIK3CA, AKT1, PTEN in HR+/HER2- Disease

• 4-Gene Methylation Panel to Expand PARPi Eligibility

Lab Operations, QA & Compliance

• Laboratory Automation: Implementation Essentials

• Optimizing Clinical Lab Operations & Testing Consolidation

• Assay Development for RNA Targets—Performance & Cost

• QC Perfection: Patient-Like Controls & Accuracy

• Enterprise CGP/HRD Automation (AVENIO Workflows)

• Value of Internalizing FDA-Authorized Tumor Profiling

• LDT Compliance in an Uncertain Regulatory Landscape

• AMP Lawsuit vs FDA: Oversight of Lab-Developed Tests

Bioinformatics, AI & Data

• Clinical Bioinformatician Body of Knowledge

• Deep Learning in Precision Medicine

• LLMs in Healthcare: Language of Innovation

• Standardization Efforts for AI in the Lab

• Open-Source Tools for Molecular Pathology

• navify & Tertiary Analysis for CGP + HRD Score

Infectious Disease & Public Health

• Next-Gen Mycology: Molecular Testing Advances

• Infectious Disease Diagnostics—From Gram Stain to NGS

• Syndromic Panels for Infectious Diseases

• Parasitology in the 21st Century: NAATs for Detection & Surveillance

• Molecular at Home & Point-of-Care Testing

• Viral Associations in Human Cancer via Genomics

Hematopathology & Myeloid/Neoplasms

• CGP Utility in Myeloid Neoplasms

• FLT3-ITD & NPM1 MRD by Sensitive NGS

• New Molecular Discoveries in B-Cell Neoplasms

Lung Cancer Guidelines & Best Practices

• 2024 CAP/IASLC/AMP Update: Molecular Testing for TKI Selection in Lung Cancer

• Difficult NSCLC Samples: Fast, Cost-Effective Profiling

• ctDNA & Ultra-Fast NGS at Diagnosis and Progression

Women’s Health, Equity & Ethics

• Disparities in Genetic Testing: Closing the Gap

• Role of Gender Identification in Genetic Testing

• Biobanking: From Pathology to Repository—Data & Sample Governance

Training, Education & Community

• Curated Resources for Training in Molecular Pathology (EdCop)

• Technologist Innovation Session

• Selected Platform Presentations (Genetics, Informatics, Tech, HemePath, ID, Solid Tumors)

• EAC Town Hall: 2024 Activities & Legislative Priorities

• Slice Testing: Ordering to Reporting—CAP/NSGC Considerations

• Case Studies: Genetics, HemePath, Solid Tumors, Infectious Diseases